|
There are more targeted treatment options available today than ever before to treat non–small cell lung cancer (NSCLC). Up to 69% of patients with advanced NSCLC could have a potentially actionable biomarker like RET.1
|
|
|
| |
RET is a known oncogenic driver in several tumor types.4 RET alterations—in the form of fusions—have been identified in NSCLC, and
up to 2% of patients with NSCLC have RET+ cancer.4-6
|
|
|
References: 1. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet.
2017;389(10066):299-311. 2. Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of cancer: results of a one-year nationwide
program of the French Cooperative Thoracic Intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients.
Lancet. 2016;287(10026):1415-1426. 3. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select
targeted drugs. JAMA. 2014;311(19):1998-2006. 4. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation
sequencing of 4,871 patients. Clin Cancer Res. 2017;23(8):1988-1997.
5. Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical
landscapes. Nat Rev Clin Oncol. 2018;15(3):151-167. 6. Lipson D, Capelletti M, Yelensky M, et al. Identification of new ALK and RET gene fusions from colorectal
and lung cancer biopsies. Nat Med. 2012;18(3):382-384.
|
